Avenue Therapeutics (ATXI)
(Delayed Data from NSDQ)
$2.72 USD
-0.15 (-5.23%)
Updated Jul 26, 2024 04:00 PM ET
After-Market: $2.62 -0.10 (-3.68%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGMFundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
ATXI 2.72 -0.15(-5.23%)
Will ATXI be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for ATXI based on the 1-3 month trading system that more than doubles the S&P 500.
Other News for ATXI
Avenue Therapeutics Stockholders Approve Key Proposals
Avenue Therapeutics to Present at the H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference
Avenue Therapeutics (ATXI) Gets a Buy from Maxim Group
Avenue Therapeutics GAAP EPS of $15.40 beats by $24.40
Avenue Therapeutics Announces Last Patient Last Visit in Phase 1b/2a Clinical Trial of AJ201 for the Treatment of Spinal and Bulbar Muscular Atrophy (Kennedy's Disease)